Walking the tightrope
November 12, 2013
Some secondary endpoints reached
July 16, 2012
The rumours were right and GlaxoSmithKline has won the day to acquire Human Genome Sciences, raising its original offer by $1.25 to $14.25 per share.
May 18, 2012
Human Genome Sciences has adopted a shareholder rights plan in the face of GlaxoSmithKline's hostile offer and has again dismissed the latter's $2.60 billion bid as inadequate
April 20, 2012
In confirming its unsolicited $2.60 billion bid for Human Genome Sciences, which has been rejected, GlaxoSmithKline says it still hopes to push through the deal "on a friendly basis"
March 11, 2011
Analysts have been reflecting on the US approval granted to Human Genome Sciences and GlaxoSmithKline's lupus drug Benlysta and what it means for patients and the two companies
PharmaTimes 2013 Copyright | RSS Feed Subscriptions